Adjuvant treatment delay in breast cancer patients
Main Author: | |
---|---|
Publication Date: | 2015 |
Other Authors: | , , |
Format: | Article |
Language: | eng |
Source: | Revista da Associação Médica Brasileira (Online) |
Download full: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302015000500411 |
Summary: | Summary Background: to evaluate if time between surgery and the first adjuvant treatment (chemotherapy, radiotherapy or hormone therapy) in patients with breast cancer is a risk factor for lower overall survival (OS). Method: data from a five-year retrospective cohort study of all women diagnosed with invasive breast cancer at an academic oncology service were collected and analyzed. Results: three hundred forty-eight consecutive women were included. Time between surgery and the first adjuvant treatment was a risk factor for shorter overall survival (HR=1.3, 95CI 1.06-1.71, p=0.015), along with negative estrogen receptor, the presence of lymphovascular invasion and greater tumor size. A delay longer than 4 months between surgery and the first adjuvant treatment was also associated with shorter overall survival (cumulative survival of 80.9% for delays ≤ 4 months vs. 72.6% for delays > 4 months; p=0.041, log rank test). Conclusion: each month of delay between surgery and the first adjuvant treatment in women with invasive breast cancer increases the risk of death in 1.3-fold, and this effect is independent of all other well-established risk factors. Based on these results, we recommend further public strategies to decrease this interval. |
id |
AMB-1_d81e1557cd7f73a25aca373bb3d2d279 |
---|---|
oai_identifier_str |
oai:scielo:S0104-42302015000500411 |
network_acronym_str |
AMB-1 |
network_name_str |
Revista da Associação Médica Brasileira (Online) |
repository_id_str |
|
spelling |
Adjuvant treatment delay in breast cancer patientsbreast neoplasmstime-to-treatmentprognosissurvivalhealth care quality assuranceSummary Background: to evaluate if time between surgery and the first adjuvant treatment (chemotherapy, radiotherapy or hormone therapy) in patients with breast cancer is a risk factor for lower overall survival (OS). Method: data from a five-year retrospective cohort study of all women diagnosed with invasive breast cancer at an academic oncology service were collected and analyzed. Results: three hundred forty-eight consecutive women were included. Time between surgery and the first adjuvant treatment was a risk factor for shorter overall survival (HR=1.3, 95CI 1.06-1.71, p=0.015), along with negative estrogen receptor, the presence of lymphovascular invasion and greater tumor size. A delay longer than 4 months between surgery and the first adjuvant treatment was also associated with shorter overall survival (cumulative survival of 80.9% for delays ≤ 4 months vs. 72.6% for delays > 4 months; p=0.041, log rank test). Conclusion: each month of delay between surgery and the first adjuvant treatment in women with invasive breast cancer increases the risk of death in 1.3-fold, and this effect is independent of all other well-established risk factors. Based on these results, we recommend further public strategies to decrease this interval.Associação Médica Brasileira2015-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302015000500411Revista da Associação Médica Brasileira v.61 n.5 2015reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/1806-9282.61.05.411info:eu-repo/semantics/openAccessTrufelli,Damila CristinaMatos,Leandro Luongo deSanti,Patricia XavierDel Giglio,Auroeng2015-11-19T00:00:00Zoai:scielo:S0104-42302015000500411Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2015-11-19T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false |
dc.title.none.fl_str_mv |
Adjuvant treatment delay in breast cancer patients |
title |
Adjuvant treatment delay in breast cancer patients |
spellingShingle |
Adjuvant treatment delay in breast cancer patients Trufelli,Damila Cristina breast neoplasms time-to-treatment prognosis survival health care quality assurance |
title_short |
Adjuvant treatment delay in breast cancer patients |
title_full |
Adjuvant treatment delay in breast cancer patients |
title_fullStr |
Adjuvant treatment delay in breast cancer patients |
title_full_unstemmed |
Adjuvant treatment delay in breast cancer patients |
title_sort |
Adjuvant treatment delay in breast cancer patients |
author |
Trufelli,Damila Cristina |
author_facet |
Trufelli,Damila Cristina Matos,Leandro Luongo de Santi,Patricia Xavier Del Giglio,Auro |
author_role |
author |
author2 |
Matos,Leandro Luongo de Santi,Patricia Xavier Del Giglio,Auro |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Trufelli,Damila Cristina Matos,Leandro Luongo de Santi,Patricia Xavier Del Giglio,Auro |
dc.subject.por.fl_str_mv |
breast neoplasms time-to-treatment prognosis survival health care quality assurance |
topic |
breast neoplasms time-to-treatment prognosis survival health care quality assurance |
description |
Summary Background: to evaluate if time between surgery and the first adjuvant treatment (chemotherapy, radiotherapy or hormone therapy) in patients with breast cancer is a risk factor for lower overall survival (OS). Method: data from a five-year retrospective cohort study of all women diagnosed with invasive breast cancer at an academic oncology service were collected and analyzed. Results: three hundred forty-eight consecutive women were included. Time between surgery and the first adjuvant treatment was a risk factor for shorter overall survival (HR=1.3, 95CI 1.06-1.71, p=0.015), along with negative estrogen receptor, the presence of lymphovascular invasion and greater tumor size. A delay longer than 4 months between surgery and the first adjuvant treatment was also associated with shorter overall survival (cumulative survival of 80.9% for delays ≤ 4 months vs. 72.6% for delays > 4 months; p=0.041, log rank test). Conclusion: each month of delay between surgery and the first adjuvant treatment in women with invasive breast cancer increases the risk of death in 1.3-fold, and this effect is independent of all other well-established risk factors. Based on these results, we recommend further public strategies to decrease this interval. |
publishDate |
2015 |
dc.date.none.fl_str_mv |
2015-10-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302015000500411 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302015000500411 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1806-9282.61.05.411 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Médica Brasileira |
publisher.none.fl_str_mv |
Associação Médica Brasileira |
dc.source.none.fl_str_mv |
Revista da Associação Médica Brasileira v.61 n.5 2015 reponame:Revista da Associação Médica Brasileira (Online) instname:Associação Médica Brasileira (AMB) instacron:AMB |
instname_str |
Associação Médica Brasileira (AMB) |
instacron_str |
AMB |
institution |
AMB |
reponame_str |
Revista da Associação Médica Brasileira (Online) |
collection |
Revista da Associação Médica Brasileira (Online) |
repository.name.fl_str_mv |
Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB) |
repository.mail.fl_str_mv |
||ramb@amb.org.br |
_version_ |
1754212831577767936 |